Clinical Trials Search
Clinical Trial 20557
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT03815058
Phase: Phase II
Prinicipal Investigator: Ahmad Tarhini
Study Title
A Phase II, Open-Label, Multicenter, Randomized Study of Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
Summary
Objective
Objectives: This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma. Specific objectives and corresponding endpoints for the study are outlined below. Primary Efficacy Objective The primary efficacy objective for this study is to evaluate the efficacy of RO7198457 plus pembrolizumab compared with pembrolizumab alone on the basis of the following endpoints: & 61623; PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Therapies
Medications
Inclusion Criteria:
Exclusion criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.